Category Archive: NEJM

A Neglected Epidemic

Imagine a global epidemic with more than 10 million new cases and 1.7 million deaths in a single year, far greater than the 28,600 cases and 11,315 deaths that were caused by Ebola virus disease in West Africa in 2014 and 2015. In addition, this imagin…

Nudge Units to Improve the Delivery of Health Care

The final common pathway for the application of nearly every advance in medicine is human behavior. No matter how effective a drug, how protective a vaccine, or how targeted a therapy may be, a clinician usually has to prescribe it, and a patient accep…

Elimination of Cost Sharing for Screening Mammography in Medicare Advantage Plans

An extensive body of evidence, including a landmark clinical trial, has shown that cost sharing — requiring people to pay for health care in the form of a deductible, copayment, or other out-of-pocket expense — reduces the use of health services. Cost sharing deters the use of effective, but often…

E-Cigarettes and the Harm-Reduction Continuum

On July 28, 2017, the recently appointed commissioner of the Food and Drug Administration (FDA), Scott Gottlieb, announced a “new comprehensive plan for tobacco and nicotine regulation.” To permit both scientific deliberation and product innovation, th…

Redefining Hypertension — Assessing the New Blood-Pressure Guidelines

Like physical guidelines designed to ensure that hikers stay on the safest path through tricky terrain, expert medical guidelines aim to steer clinicians toward best practices. The new Guideline for the Prevention, Detection, Evaluation, and Management…

In-Person Health Care as Option B

What if health care were designed so that in-person visits were the second, third, or even last option for meeting routine patient needs, rather than the first? This question seems to elicit two basic responses — sometimes expressed in the same breath: “The idea will upset many physicians, who are…

Rejuvenating Regenerative Medicine Regulation

The Food and Drug Administration (FDA) recently made long-awaited progress toward protecting patients from interventions involving human cell- and tissue-based products (HCT/P) of unknown safety and efficacy. By clarifying its position on the handling …

When the CHIPs Are Down — Health Coverage and Care at Risk for U.S. Children

Despite bipartisan agreement on a 5-year plan in both the Senate and the House of Representatives, Congress failed to reauthorize the Children’s Health Insurance Program (CHIP) last fall, causing uncertainty and worry for families and state CHIP directors alike. Families in several states,…

Federal Right-to-Try Legislation — Threatening the FDA’s Public Health Mission

The Food and Drug Administration (FDA) is the gatekeeper of the country’s drugs and medical devices. Originally created to prevent the misleading of patients, it was later tasked with ensuring the safety of medical products. In 1962, Congress expanded the FDA’s mandate again, requiring it to…

Toward a Culture of Scientific Inquiry — The Role of Medical Teaching Services

A major goal of academic medicine is to link patient care to scientific inquiry. The value of this linkage for understanding human biology has been recognized for over a century. Postmortem examinations of patients with aphasia drove the localization o…

Older posts «

Explore the Archive